GT Biopharma Stock
GT Biopharma, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Michael Martin Breen
- Employees
- 1
- Market cap
- $9 M
- IPO
- 27/03/2018
GT Biopharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and bringing to market novel immuno-oncology treatments. Their innovative approach centers on a proprietary technology platform called Tri-specific Killer Engager (TriKE) fusion proteins, which are designed to…
GT Biopharma stock: price history
1D
-4.5%
1W
+5.2%
1M
-10.0%
6M
-25.8%
YTD
-64.2%
1Y
-58.8%
2Y
-85.9%
5Y
-99.8%
10Y
-100.0%
Next earnings date
Next earnings date
13/11/2026 (in 27 days)
Volatility around earnings
~14% stronger price swings than usual
Ask the agents about GT Biopharma
Analyst assessment of GT Biopharma
0
STRONG BUY
4
BUY
1
HOLD
0
SELL
0
STRONG SELL
5
TOTAL · Buy
As of: 07/08/2023
GT Biopharma stock metrics
P/E
-0.07
P/B
3.06
EV/EBITDA
-0.19
RETURN ON EQUITY
-126.6%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
106.1%
FLOAT SHARES
1,338,742
AVG. DAILY VOLUME (30D)
98,589
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about GT Biopharma stock
What does GT Biopharma do?
GT Biopharma, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Michael Martin Breen, the company employs around 1 people.
The IPO was on 27/03/2018; the stock trades on NASDAQ under the ticker GTBP.
What do analysts say about GT Biopharma stock?
5 analysts rate the stock, the consensus is Buy (as of 07/08/2023).
This is an external assessment, not a statement by Market Jury.
When does GT Biopharma report next?
The next earnings date is 13/11/2026.
Around past earnings, price swings were roughly 14% stronger than usual.
Does GT Biopharma pay a dividend?
No, GT Biopharma currently does not pay a dividend.
Which stocks are comparable to GT Biopharma?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get GT Biopharma stock analyzed?
Clicking "Analyze stock" lets five strategies assess GT Biopharma against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.